MindImmune Therapeutics Announces $12.4 million Series A Financing | MindImmune Therapeutics, Inc.
Summary
Use of proceeds of the financing will support MindImmune in advancing its lead program in preclinical development, targeting Alzheimers disease as the primary indication.MindImmune was launched by co-founders Stevin Zorn, Ph.D, Frank Menniti, Ph.D. and Robert Nelson, Ph.D., who originally met as scientific collaborators in central nervous system (CNS) research at Pfizer. MindImmune aims to develop a novel therapeutic antibody to act in the peripheral system to block immune cells from causing neural damage, thereby reducing cognitive symptoms and slowing progression of this devastating disease. With the resources provided, we are excited to accelerate our preclinical R&D activities, aiming to advance our lead program to IND candidate stage.According to Tracy Saxton, Ph.D., Managing Director at Dolby Family Ventures, MindImmune has distinguished itself in pioneering a potentially fundamental new approach to modulate the innate immune response in Alzheimers disease. This assay is designed to quantify the amount of peripheral immune cells recruited into the CNS in Alzheimers disease as well as potentially serve as a diagnostic and/or biomarker of neuroinflammation in patients afflicted with Alzheimers, aiding the broader R&D community as well as MindImmunes internal program.About MindImmuneMindImmune Therapeutics Inc. is a venture-backed, drug discovery company co-founded by veteran central nervous system drug discovery scientists Stevin Zorn, Ph.D., Frank Menniti, Ph.D. and Robert Nelson, Ph.D., formerly colleagues within Worldwide Research & Development at Pfizer. Based at the University of Rhode Island, MindImmune benefits from an affiliation with the George & Anne Ryan Institute for Neuroscience, Kingston, RI.For more information, contact:Laura Nelson or Sage Morander SVM Public Relations401.490.9700laura.nelson@svmpr.com sage.morander@svmpr.com